National Resource Center for Academic Detailing [NaRCAD]
NARCAD
  • About
    • Why We Matter
    • Testimonials
    • Our Team
    • Contact Us
  • Tools & Resources
    • AD Core Toolkits >
      • Inclusivity Toolkit
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
      • E-Detailing Toolkit
      • Materials Toolkit
    • AD Literature Archives
  • Webinars
    • Webinar Series
    • E-Detailing Webinars
    • E-Detailing Roundtables
  • Blog & E-News
    • Best Practices Blog
    • E-Newsletter
  • Community
    • Discussion Forum
    • Peer Connection Program
    • Detailing Partners
  • EVENTS
    • Training Series
    • CONFERENCE SERIES
    • AD Summit Series
    • Present at NaRCAD2023
    • THE CONFERENCE HUB
  • About
    • Why We Matter
    • Testimonials
    • Our Team
    • Contact Us
  • Tools & Resources
    • AD Core Toolkits >
      • Inclusivity Toolkit
      • Opioid Safety Toolkit
      • HIV Prevention Toolkit
      • E-Detailing Toolkit
      • Materials Toolkit
    • AD Literature Archives
  • Webinars
    • Webinar Series
    • E-Detailing Webinars
    • E-Detailing Roundtables
  • Blog & E-News
    • Best Practices Blog
    • E-Newsletter
  • Community
    • Discussion Forum
    • Peer Connection Program
    • Detailing Partners
  • EVENTS
    • Training Series
    • CONFERENCE SERIES
    • AD Summit Series
    • Present at NaRCAD2023
    • THE CONFERENCE HUB

The DETAILS BLOG

Capturing Stories from the Field: Reflections, Challenges, & Best Practices

​Is the Nation Making a U-turn on Regulating Drug Promotion?

7/14/2015

0 Comments

 
Jerry Avorn, MD, NaRCAD Co-Director

Tags: Detailing Visits, Health Policy, Jerry Avorn, Medications

For over a century, appropriate medication use in the U.S. has relied heavily on the regulation of what manufacturers can say about their products.  One of the first powers given to the Food and Drug Administration when it was created in 1906 was the ability to require that makers of “patent medicines” state what was actually in their products. (Often, it was a mixture of ineffective ingredients laced with alcohol or opium, but accurate information was a start.) Over time, the agency was granted the authority to regulate claims about efficacy and safety that companies made about prescription drugs.

This has begun to change, with potentially important implications for academic detailing. Currently drug manufacturers promoting their medications to clinicians are limited to discussing indications for which they have obtained approval from FDA, Last year, however, FDA announced its openness to considering policies to make it easier for drug manufacturers to present doctors with their own views about off-label uses of their products that FDA did not consider appropriate. A follow-up “draft guidance” would similarly open the door for manufacturers to provide information about side effects that differs from the determinations of FDA scientists and outside advisers.

Most recently, the agency has revealed plans for a national conference on whether limiting drug-makers’ promotional statements might infringe on these companies’ corporate free speech rights. And a bill that has progressed through Congress, The 21st Century Cures Act, will make it easier for drugs to be approved on the basis of looser standards, including lab tests or other surrogate measures of efficacy rather than actual patient outcomes.

These developments will have important implications for academic detailing. If we are entering a period of lessened government regulation of what pharmaceutical manufacturers are permitted to tell prescribers about off-label uses of their products, or their safety profiles, there will be an even greater need for balanced, evidence-based communication to inform medication use decisions. Just as travelers to developing countries that have polluted water supplies often prefer to drink bottled water, clinicians may increasingly feel the need for access to non-contaminated information sources if they can’t be sure what’s coming out of an increasingly de-regulated informational tap.

All of us concerned with optimal use of medications will need to monitor these developments closely.  If the proposed changes prevent FDA from regulating the promotional claims made by drug manufacturers as closely as in the past, then health care systems and individual practitioners will have increasingly greater need for the more reliable sources of information that academic detailing services can provide. Stay tuned.
0 Comments



Leave a Reply.

    Highlighting Best Practices

    We highlight what's working in clinical education through interviews, features, event recaps, and guest blogs, offering clinical educators the chance to share successes and lessons learned from around the country & beyond.

    Search Archives
    by Topic:

    All
    Autism
    Cancer
    Cardiovascular Health
    Chronic Illness
    CME
    Conference
    COVID 19
    Data
    Deprescribing
    Detailing Visits
    Diabetes
    Director's Letter
    E Detailing
    Elderly Care
    Evaluation
    Evidence Based Medicine
    Expert Trainer Insight Series
    Harm Reduction
    Health Disparities
    Health Policy
    Hepatitis C
    HIV/AIDS
    International
    Jerry Avorn
    LOOPR
    Materials Development
    Medications
    Mental Health
    Obesity
    Opioid Safety
    Pediatrics
    Practice Facilitation
    PrEP
    Primary Care
    Program Management
    Rural AD Programs
    Sexual Health
    Smoking Cessation
    Stigma
    Substance Use
    Sustainability
    Training
    Vaccinations

    RSS Feed


​NaRCAD is a program of the Boston Medical Center, founded at the Division of Pharmacoepidemiology & Pharmacoeconomics [DoPE], at Brigham & Women's Hospital.

​Privacy Notice
Proudly powered by Weebly